相似文献
1
Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
J Transl Med. 2018 Jun 29;16(1):179. doi: 10.1186/s12967-018-1552-1.
2
Correction to: Comparative proteomic analysis of Tibetan pig spermatozoa at high and low altitudes.
BMC Genomics. 2019 Aug 1;20(1):626. doi: 10.1186/s12864-019-5993-6.
3
Correction to: The past, present and future of opioid withdrawal assessment: a scoping review of scales and technologies.
BMC Med Inform Decis Mak. 2019 Jul 8;19(1):126. doi: 10.1186/s12911-019-0851-7.
4
Correction to: ThalPred: a web-based prediction tool for discriminating thalassemia trait and iron deficiency anemia.
BMC Med Inform Decis Mak. 2019 Nov 19;19(1):228. doi: 10.1186/s12911-019-0977-7.
5
Correction to: Hospital organizational context and delivery of evidence-based stroke care: a cross-sectional study.
Implement Sci. 2019 Feb 8;14(1):13. doi: 10.1186/s13012-019-0862-x.
6
Correction to: Prevention of seroma following inguinal lymph node dissection with prophylactic, incisional, negative-pressure wound therapy (SEROMA trial): study protocol for a randomized controlled trial.
Trials. 2018 Oct 19;19(1):570. doi: 10.1186/s13063-018-2882-2.
7
Correction to: Associations of serum 25-hydroxyvitamin D with metabolic syndrome and its components in elderly men and women: the Korean Urban Rural Elderly cohort study.
BMC Geriatr. 2019 May 8;19(1):131. doi: 10.1186/s12877-019-1150-y.
8
Correction to: Effects of probiotics on type II diabetes mellitus: a meta-analysis.
J Transl Med. 2020 Feb 28;18(1):105. doi: 10.1186/s12967-020-02274-3.
9
Author Correction: Large-scale transcriptome-wide association study identifies new prostate cancer risk regions.
Nat Commun. 2019 Jan 8;10(1):171. doi: 10.1038/s41467-018-08108-7.
10
Correction to: Harnessing Qatar Biobank to understand type 2 diabetes and obesity in adult Qataris from the First Qatar Biobank Project.
J Transl Med. 2018 Oct 15;16(1):283. doi: 10.1186/s12967-018-1648-7.
引用本文的文献
1
Immunotherapy in the context of immune-specialized environment of brain metastases.
Discov Immunol. 2023 Nov 16;2(1):kyad023. doi: 10.1093/discim/kyad023. eCollection 2023.
2
Drug resistance in glioblastoma: from chemo- to immunotherapy.
Cancer Drug Resist. 2023 Oct 11;6(4):688-708. doi: 10.20517/cdr.2023.82. eCollection 2023.
3
Application of injectable hydrogels in cancer immunotherapy.
Front Bioeng Biotechnol. 2023 Feb 3;11:1121887. doi: 10.3389/fbioe.2023.1121887. eCollection 2023.
4
Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-Analysis.
Cancer Control. 2022 Jan-Dec;29:10732748221079474. doi: 10.1177/10732748221079474.
5
The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis.
J Neurooncol. 2022 Jan;156(2):257-267. doi: 10.1007/s11060-021-03940-2. Epub 2022 Jan 4.
6
Immunotherapeutic early-phase clinical trials and malignant gliomas: A single-center experience and comprehensive immunophenotyping of circulating leukocytes.
Neurooncol Adv. 2021 Nov 13;3(1):vdab160. doi: 10.1093/noajnl/vdab160. eCollection 2021 Jan-Dec.
7
Characterization and Manipulation of the Crosstalk Between Dendritic and Natural Killer Cells Within the Tumor Microenvironment.
Front Immunol. 2021 May 14;12:670540. doi: 10.3389/fimmu.2021.670540. eCollection 2021.
8
Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.
Cancer Biol Med. 2020 Aug 15;17(3):555-568. doi: 10.20892/j.issn.2095-3941.2020.0027.
9
Immunotherapy Against Gliomas: is the Breakthrough Near?
Drugs. 2019 Nov;79(17):1839-1848. doi: 10.1007/s40265-019-01203-z.
10
Newly Diagnosed Glioblastoma: A Review on Clinical Management.
Oncology (Williston Park). 2019 Mar 13;33(3):91-100.
本文引用的文献
1
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6.
Zotero 插件